Related content

Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety

By Guo Feng   Letrent Stephen   Munster Pamela   Britten Carolyn   Gelmon Karen   Tolcher Anthony   Sharma Amarnath  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 1, 2008-06 ,pp. : 97-109

Springer Publishing Company

Access to resources Recommend Favorite

Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US

By Cronin Kathleen A.   Harlan Linda C.   Dodd Kevin W.   Abrams Jeffrey S.   Ballard-Barbash Rachel  

Cancer Investigation, Vol. 28, Iss. 9, 2010-10 ,pp. : 963-968

Informa Healthcare

Access to resources Recommend Favorite

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

By Valabrega Giorgio  

Breast Cancer Research and Treatment, Vol. 130, Iss. 1, 2011-11 ,pp. : 29-40

Springer Publishing Company

Access to resources Recommend Favorite

HER2-positive gastric cancer

By Boku Narikazu  

Gastric Cancer, Vol. 17, Iss. 1, 2014-01 ,pp. : 1-12

Springer Publishing Company

Access to resources Recommend Favorite

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia   Pronzato Paolo   Del Mastro Lucia  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite